Effectiveness and safety of generic and brand direct acting antivirals for treatment of chronic hepatitis C

Table 3 Predictors of not achieving sustained virologic response in patients receiving only sofosbuvir-based therapy identified using a multivariable regression model, n = 223

Variable	No SVR, n (%)	Crude OR (95%CI)	Adjusted OR (95%CI)	Adjusted P
Age (yr)
< 40	5 (7.5)	1	1
40-65	6 (4.5)	0.58 (0.17-1.98)	0.30 (0.07-1.35)	0.12
> 65	20 (9.1)	1.24 (0.22-6.89)	0.69 (0.08-5.81)	0.73
Sex
Female	4 (4.3)	1	1
Male	9 (6.9)	1.66 (0.49-5.55)	2.33 (0.57-9.53)	0.24
Co-morbidities
None	2 (2.6)	1	1
0ne to two	7 (6.3)	2.47 (0.50-12.21)	1.03 (0.14-7.61)	0.98
More than two	4 (11.4)	4.77 (0.83-27.43)	3.45 (0.41-29.05)	0.26
USD cirrhosis
No	4 (2.6)	1	1
Yes	9 (13.2)	5.76 (1.71-19.42)	8.99 (1.83-44.16)	0.007
HCV genotype
1	6 (4.1)	1	1
3	6 (12.2)	3.30 (1.01-10.77)	4.44 (1.17-16.89)	0.03
4	1 (3.8)	0.95 (0.11-8.20)	0.95 (0.10-9.45)	0.96
DAC regimen
Generic	6 (4.3)	1	1
Brand	7 (8.4)	2.06 (0.67-6.34)	1.42 (0.34-5.94)	0.63
WBC (× 109/L)		0.98 (0.80-1.21)
Haemoglobin (g/dL)		1.15 (0.89-1.48)
Platelets (× 109/L)		1.00 (0.99-1.01)
PT (sec)		1.02 (0.95-1.06)
PTT (sec)		1.17 (1.00-1.37)
INR		1.00 (0.72-1.38)
Creatinine (μmol/L)		1.00 (0.97-1.03)
Albumin (g/L)		0.97 (0.90-1.06)
Total bilirubin (μmol/L)		0.99 (0.95-1.03)
ALP (U/L)		1.01 (1.00-1.02)
ALT (U/L)		1.01 (1.00-1.02)
gGT(U/L)		1.03 (1.00-1.07)

HCV: Hepatitis C virus; WBC: White blood cell count; USD: Ultrasound-diagnosed; PT: Prothrombin time; PTT: Partial thromboplastin time; INR: International normalized ratio; ALP: Alkaline phosphatase; ALT: Alanine aminotransferase; gGT: Gamma-glutamyl transpeptidase; SVR: Sustained virologic response; 95%CI: 95% confidence interval; OR: Odds ratio.